Efficacy of nodal dissection for treatment of persistent/recurrent papillary thyroid cancer

Laryngoscope

Volumn 118, Issue 5, 2008, Pages 768-775

  Schuff, Kathryn G ^a   Weber, Stephen M ^b   Givi, Babak ^b   Samuels, Mary H ^a   Andersen, Peter E ^b   Cohen, James I ^b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Neck dissection; Papillary thyroid cancer; Radioiodine; Recurrence; Thyroglobulin; Thyroidectomy

Indexed keywords

THYROGLOBULIN;

ABSCESS; ADOLESCENT; ADULT; AGED; ARTICLE; CANCER STAGING; CELLULITIS; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; FEMALE; HEMATOMA; HUMAN; HYPOPARATHYROIDISM; KELOID; LUNG EMBOLISM; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; NERVE PARALYSIS; OUTCOME ASSESSMENT; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RECURRENT CANCER; SEROMA; THYROID CANCER; TRACHEOSTOMY;

ADOLESCENT; ADULT; AGED; ALGORITHMS; CARCINOMA, PAPILLARY; FEMALE; HUMANS; LYMPH NODE EXCISION; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PATIENT CARE TEAM; POSTOPERATIVE COMPLICATIONS; RETROSPECTIVE STUDIES; SURGICAL PROCEDURES, OPERATIVE; THYROGLOBULIN; THYROID NEOPLASMS; TREATMENT OUTCOME;

EID: 43049097521     PISSN: 0023852X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MLG.0b013e318162cae9     Document Type: Article

References (38)

1. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994;97:418-428.
2. Samaan NA, Maheswari YK, Nader S, et al. Impact of therapy for differentiated thyroid carcinoma: an analysis of 706 cases. J Clin Endocrinol Metab 1983;56:1131-1138.
3. Tubiana M, Schlumberger M, Rougler P, et al. Long term results and prognostic factors in patients with differentiated thyroid carcinoma. Cancer 1985;55:794-804.
4. Palme CE, Waseem A, Raza N, Eski S, Walfish P, Freeman JL. Management and outcome of recurrent well-differentiated thyroid carcinoma. Arch Otolaryngol Head Neck Surg 2004;130:819-824.
5. Mazzaferri EL, Robbins RJ, Spencer CA, et al. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab 2003;88:1433-1441.
6. Cooper DS, Doherty GM, Haugen BR, et al., for the American Thyroid Association Guidelines Task Force. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2006;16:1-33.
7. Coburn M, Teates D, Wanebo HJ. Recurrent thyroid cancer. Role of surgery versus radioactive iodine (I131). Ann Surg 1994;219:587-593.
8. Travagli JP, Cailleux AF, Ricard M, et al. Combination of radioiodine (I131) and probe-guided surgery for persistent or recurrent thyroid carcinoma. J Clin Endocrinol Metab 1998;83:2675-2680.
9. Kloos RT, Mazzaferri EL. A single recombinant human thyrotropin- stimulated serum thyroglobulin measurement predicts differentiated thyroid carcinoma metastases three to five years later. J Clin Endocrinol Metab 2005;90:5047-5057.
10. Alzahrani AS, Raef H, Sultan A, et al. Impact of cervical lymph node dissection on serum TG and the course of disease in TG-positive, radioactive iodine whole body scan-negative recurrent/persistent papillary thyroid cancer. J Endocrinol Invest 2002;25:526-531.
11. Maxon HR, Englaro EE, Thomas SR, et al. Radioiodine-131 therapy for well-differentiated thyroid cancer - a quantitative radiation dosimetric approach: outcome and validation in 85 patients. J Nucl Med 1992;33:132-136.
12. Robbins RJ, Larson SM, Pentlow K, Tuttle RM. Effectiveness of I-131 in destroying metastatic thyroid cancer lesions [Abstract]. Thyroid 2002;12:199.
13. Yehuda MN, Freeman JL. Revision central compartment surgery: indications, management and outcomes in 60 consecutive patients[Abstract]. Presented at: Annual Meeting of the American Head and Neck Society; April 28, 2007; San Diego, CA.
14. Rosario PW, Maia FF, Cardoso LD, et al. Correlation between cervical uptake and results of postsurgical radioiodine ablation in patients with thyroid carcinoma. Clin Nucl Med 2004;29:358-361.
15. Dam HQ, Kim SM, Lin HC, Intenzo CM. 131I therapeutic efficacy is not influenced by stunning after diagnostic whole-body scanning. Radiology 2004;232:527-533.
16. Pacini F, Cetani F, Miccoli P, et al. Outcome of 309 patients with metastatic differentiated thyroid carcinoma treated with radioiodine. World J Surg 1994;18:600-604.
17. Qubain SW, Nakano S, Baba M, Takao S, Aikou T. Distribution of lymph node micrometastasis in pN0 well-differentiated thyroid carcinoma. Surgery 2002;131:249-256.
18. Wada N, Duh QY, Sugino K, et al. Lymph node metastasis from 259 papillary thyroid microcarcinomas: frequency, pattern of occurrence and recurrence, and optimal strategy for neck dissection. Ann Surg 2003;237:399-407.
19. Roh JL, Park JY, Rha KS, Park CI. Is central neck dissection necessary for the treatment of lateral cervical nodal recurrence of papillary thyroid carcinoma? Head Neck 2007;29:901-906.
20. Musacchio MJ, Kim AW, Vijungco JD, Prinz RA. Greater local recurrence occurs with "berry picking" than neck dissection in thyroid cancer. Am Surg 2003;69:191-197.
21. Cheah WK, Arici C, Ituarte PH, Siperstein AE, Duh QY, Clark OH. Complications of neck dissection for thyroid cancer. World J Surg 2002;26:1013-1016.
22. Kim MK, Mandel SH, Baloch Z, et al. Morbidity following central compartment reoperation for recurrent or persistent thyroid cancer. Arch Otolaryngol Head Neck Surg 2004;130:1214-1216.
23. Warren FM, Andersen PE, Wax MK, Cohen JI. Perioperative parathyroid hormone levels in thyroid surgery: preliminary report. Laryngoscope 2004;114:689-693.
24. Warren FM, Andersen PE, Wax MK, Cohen JI. Intraoperative parathyroid hormone levels in thyroid and parathyroid surgery. Laryngoscope 2002;112:1866-1870.
25. Ghaheri BA, Liebler SL, Andersen PE, et al. Perioperative parathyroid hormone levels in thyroid surgery. Laryngoscope 2006;116:518-521.
26. Noguchi S, Muarkami N, Yamashita H, Toda M, Kawamoto H. Papillary thyroid carcinoma: modified radical neck dissection improves prognosis. Arch Surg 1998;133:276-280.
27. Shindo M, Wu JC, Park EE, Tanzella F. The importance of central compartment elective lymph node excision in the staging and treatment of papillary thyroid cancer. Arch Otolaryngol Head Neck Surg 2006;132:650-654.
28. Henry JF, Gramatica L, Denizot A, Kvachenyuk A, Puccini M, Defechereux T. Morbidity of prophylactic lymph node dissection in the central neck area in patients with papillary thyroid carcinoma. Langenbecks Arch Surg 1998;383:167-169.
29. Kupferman ME, Patterson DM, Mandel SJ, LiVolsi V, Weber RS. Safety of modified radical neck dissection for differentiated thyroid carcinoma. Laryngoscope 2004;114:403-406.
30. Pereira JA, Jimeno J, Miquel J, Iglesias, Munne A, Sancho JJ. Nodal yield, morbidity, and recurrence after central neck dissection for papillary thyroid carcinoma. Surgery 2005;138:1095-1100.
31. Steinmuller T, Klupp J, Wenking S, Neuhaus P. Complications associated with different surgical approaches to differentiated thyroid carcinoma. Langenbecks Arch Surg 1999;384:50-53.
32. Jaskowiak N, Norton JA, Alexander HR, et al. A prospective trial evaluating a standard approach to reoperation for missed parathyroid adenoma. Ann Surg 1996;224:308-320.
33. Mariette C, Pellissier L, Combemale F, Quievreux JL, Carnaille B, Proye C. Reoperation for persistent or recurrent primary hyperparathyroidism. Langenbecks Arch Surg 1998;383:174-179.
34. Shen W, Duren M, Morita E, et al. Reoperation for persistent or recurrent primary hyperparathyroidism. Arch Surg 1996;131:861-867.
35. Valadao MM, Rosario PW, Borges MA, et al. Positive predictive value of detectable stimulated Tg during the first year after therapy of thyroid cancer and the value of comparison with Tg-ablation and Tg measured after 24 months. Thyroid 2006;16:1145-1149.
36. Toubeau M, Touzery C, Arveux P, et al. Predictive value for disease progression of serum thyrodglobulin levels measured in the postoperative period and after (131)I ablation therapy in patients with differentiated thyroid cancer. J Nucl Med 2004;45:988-994.
37. Cross S, Wei JP, Kim S, Brams DM. Selective surgery and adjuvant therapy based on risk classifications of well-differentiated thyroid cancer. J Surg Oncol 2006;94:678-682.
38. Noguchi M, Kumaki T, Taniya T, et al. Impact of neck dissection on survival in well-differentiated thyroid cancer: a multivariate analysis of 218 cases. Int Surg 1990;75:220-224.